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In living cells proteins function together 
as the basic machinery of life. The produc-
tion of functional proteins can be parti-
tioned to specific hierarchical steps known 
as central dogma activities, comprising 
transcription, translation, and post-trans-
lational modifications (PTMs). These 
highly coordinated biochemical processes 
rely on the subdivision of the reactions 
into different cellular compartments, 
allowing precise control over the final 
products. In particular, site-specific PTMs, 
such as phosphorylation, glycosylation, 
and ubiquitination, allow to further extend 
the functionality of proteins by yielding a 
wide range of protein variants consisting 
of the same amino acid sequences. While 
this set of discrete reactions has naturally 
evolved over millions of years, synthetic 
approaches aimed to allow such control 
have been recently developed to generate 
cell-free artificial cell platforms.[1–4]
One of the main advantages of cell-
free systems (CFSs) is the reduction of 
the intricate cellular environment into its 
essential components.[5,6] Since their original impact in eluci-
dating the genetic code,[7] CFSs have been proven as an effec-
tive method to address fundamental questions in biology.[8] 
Moreover, CFSs have been used as a powerful synthetic 
biology tool allowing the production of complex molecules 
beyond those produced by purely synthetic chemistry, leading 
to the development of unprecedented therapeutic and diag-
nostic applications.[9–14] However, utilizing artificial cells as 
fully compartmentalized and controlled platforms, allowing 
to spatially and temporally segregate central dogma activities, 
remains challenging. Specifically, current artificial cell systems 
lack the ability to perform PTMs. When PTMs are syntheti-
cally introduced in an indiscriminate manner, their effect on a 
single protein is highly difficult to profile and characterize.[15] 
Moreover, PTMs vary between different organisms, and while 
human proteins can be exogenously expressed in various in 
vivo models, such modifications may alter the expressed pro-
teins characteristics compared to their original form.[16]
Here, we present an artificial-cell-on-chip engineered in 
a modular and programmable manner to control each of the 
central dogma activities. The new compartmentalized central 
dogma activities artificial cell (CONTRALL) system allows the 
production of modified proteins by programming transcription, 
In nature, intracellular microcompartments have evolved to allow the 
simultaneous execution of tightly regulated complex processes within a 
controlled environment. This architecture serves as the blueprint for the 
construction of a wide array of artificial cells. However, such systems are 
inadequate in their ability to confine and sequentially control multiple central 
dogma activities (transcription, translation, and post-translational modifica-
tions) resulting in a limited production of complex biomolecules. Here, an 
artificial cell-on-a-chip comprising hierarchical compartments allowing the 
processing and transport of products from transcription, translation, and 
post-translational modifications through connecting channels is designed 
and fabricated. This platform generates a tightly controlled system, yielding 
directly a purified modified protein, with the potential to produce proteoform 
of choice. Using this platform, the full ubiquitinated form of the Parkinson’s 
disease-associated α-synuclein is generated starting from DNA, in a single 
device. By bringing together all central dogma activities in a single control-
lable platform, this approach will open up new possibilities for the synthesis 
of complex targets, will allow to decipher diverse molecular mechanisms in 
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translation, and PTMs in a discrete and highly precise manner 
(Figure 1). Using this approach, we demonstrate decoupling 
of transcription from translation and control over the trans-
lation time of specific RNA transcripts. In addition, decou-
pling these processes allows selective and simple control over 
transcription activation, thus making screening of synthetic 
promotor libraries or designing complicated genetic circuits 
redundant. By integrating simple biosynthesis techniques, we 
further extend this approach to purify desired proteins on-chip, 
allowing dynamic modulation of PTMs of choice. We explored 
the ubiquitination of α-synuclein, a protein with notable aggre-
gation propensity that is associated with Parkinson’s disease 
(PD), characterized the reaction products and identified the 
ubiquitination sites. Our results reveal that by modulating 
the substrates used in the reaction, the CONTRALL platforms 
allows for precise PTMs to be incorporated within the protein 
sequence in a selective manner. This dynamic approach shows 
promise in revolutionizing current CFS methods currently used 
and could be applied to a wide range of protein-based systems.
To allow hierarchical implementation of transcription, trans-
lation, and PTMs processes, we utilized a microfluidics-based 
approach to reduce reagent usage and generate highly con-
trolled microcompartments comprising unique engineered fea-
tures. In the CONTRALL biochip (Figure 1), each process takes 
place within a different microcompartment and the product is 
isolated or allowed to move into the subsequent compartment 
by a series of engineered microfluidic valves, used as ON/
OFF switches, and size secluding pillars, which act as phys-
ical barriers for targeted elements (Figure 2a). First, aiming to 
recapitulate the natural eukaryotic cell process, we sought to 
decouple transcription from translation.[17] We developed a bio-
chip comprising of two confined parallel transcription compart-
ments with a set of controlled mechanical promotor-like valves 
(Figure 2a), thereby allowing control of transcription initiation 
and strength. The compartments were followed by a detection 
channel where mango light-up RNA aptamer could be detected 
(Figure 2a). To localize and segregate transcription in a confined 
environment, we used PDMS based lithographically defined ele-
ments to trap Ni beads bound to His-tagged T7 RNA polymerase 
(T7RP), thereby immobilizing the enzyme and preventing its 
transfer to downstream compartments (Figure 2a; Figure S1, 
Supporting Information). To verify sufficiently effective and 
accurate transcription by the immobilized T7RP, we employed 
the biochip to transcribe mango light-up RNA aptamer, which 
generates a fluorescent signal only in the presence of a specific 
fluorogene when its secondary structure remains active.[18] Fol-
lowing transcription, we have been able to detect a fluorescent 
signal from the reaction flow-through, demonstrating correct 
transcription by immobilized T7RP (Figure 2b). Expanding on 
this approach, we have been able to transcribe two different RNA 
light-up aptamers in two parallel compartments. By alternatively 
modulating the flow rate and valve shuttering of the two com-
partments, we developed an oscillator switch of RNA transcripts 
(Figure 2c). By selectively transferring different volumes of the 
RNA transcript solution, we demonstrated the controlled accu-
mulation of specific RNA transcripts in the collected fraction, 
thus mimicking mechanically promotor strength (Figure 2d). 
The immobilization of T7RP holds great potential for re-using 
the transcription compartment with different genes.
Following the establishment of confined and controlled tran-
scription processes, we aimed to mimic nuclear transport, a key 
feature in all eukaryotic cells, comprising the tightly regulated 
and highly selective mobilization of RNA transcripts from the 
nucleus to the cytoplasm.[17] First, we verified the ability of the 
immobilized T7RP to transcribe from both biotinylated and 
nonmodified DNA template molecules (Figure 2b). Following 
transcription, the solution containing RNA molecules, bioti-
nylated DNA, and other essential components was flown into 
a downstream channel comprised of immobilized streptavidin 
(SA) beads, which bound the biotinylated DNA and allowed 
RNA transcripts to continue flowing into the translation com-
partment (Figure 3a).
To avoid introducing additional background noise during 
the translation process, we used cell-free protein synthesis 
kit, PUREfrex, which comprises untagged purified transla-
tion machinery components of Escherichia coli with reduced 
contaminations.[19] These components were directly introduced 
into the translation compartment via an inlet (Figure 3a). 
Following transcription and RNA mobilization into the transla-
tion compartment, RNA molecules encoding His-tagged green 
fluorescent protein (eGFP) encountered the PUREfrex compo-
nents, facilitating the translation process. The newly translated 
His-eGFP was immobilized using Ni beads trapped inside the 
compartment. Following translation, the compartment was 
washed to remove any remaining RNA molecules and trans-
lation components, while the His-eGFP remained trapped. 
His-eGFP was then eluted from the CONTRALL biochip using 
an imidazole-based solution. Using fluorescence spectrum 
and Western blot analysis His-eGFP was detected in both the 
translation and elution solutions, but not in the flow-through 
fraction, indicated that most of the translated protein was 
trapped within the CONTRALL biochip (Figure 3b,c; Figure S2, 
Supporting Information). The CONTRALL protein yield is 
≈24 µg mL−1 per cycle.
After establishing the ability to both translate and immo-
bilize a protein of choice in a controlled environment, we 
proceeded to perform site-specific PTMs by enzymatic 
means. PTMs allow to further extend the functionality of 
proteins by yielding a wide range of protein variants con-
sisting of the same amino acid sequences. Implementing 
PTMs compartment as part of the CONTRALL platform will 
potentially allow to produce different proteins caring various 
PTMs. As a model protein, we used α-synuclein, a natively 
unfolded protein, shown to be linked to Parkinson’s disease 
(PD).[20] Understanding the molecular mechanisms under-
lying α-synuclein aggregation and identifying α-synuclein’s 
modification sites could result in more effective therapeutic 
strategies. α-synuclein has been shown to be mono- and poly-
ubiquitinated by the E3 ubiquitin ligase, Hsp70-interacting 
protein (CHIP).[21] CHIP E3 ligase was shown to reduce 
α-synuclein oligomerization and mediate the degradation 
of misfolded proteins associated with Alzheimer disease, 
Huntington and PD.[22] However, the ubiquitination sites 
in which CHIP E3 ubiquitinates α-synuclein have not been 
identified to date.[21,22] Here, His-α-synuclein was translated 
and immobilized onto Ni beads in the translation com-
partment of CONTRALL as detailed above. Following 
a washing step, we introduced in vitro ubiquitination 
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Figure 1. Cellular processing of transcription, translation and PTMs and their compartmentalization in the CONTRALL platform. a) Illustration of 
eukaryotic cell compartmentalized expression process of two genes in response to promotor activation. Following transcription in the nucleus (dashed 
grey line), RNA transcripts are transported to the cytoplasm, where they undergo translation and PTMs. b) Schematics of the CONTRALL platform 
showing parallel transcription of two genes encoding for His-tagged proteins at two spatially separated compartments. Transcription is performed 
by an immobilized T7RP trapped in the compartments. Closing the mechanical valve following transcription allows RNA transcripts from either one 
compartment or both to flow into a downstream compartment. DNA molecules are then immobilized, while RNA molecules encounter cell-free 
translation components. The resulting translated His-protein is immobilized using trapped Ni beads, allowing the removal of translation components 
and the subsequent introduction of PTMs enzymes of choice. Following incubation, PTMs enzymes are washed and the purified proteoform is eluted.
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components including CHIP E3 ligase. Following 
increased incubation times, the compartment was washed, 
yielding purified immobilized α-synuclein, which was 
eluted in a similar manner to His-eGFP. To validate 
the formation of ubiquitinated α-synuclein, Western blot 
analysis was applied, indicating that the newly formed 
α-synuclein proteoforms were both mono- and polyubiquit-
inated (Figure 3c). Using mass spectrometry, we were able to 
identify, for the first time, the CHIP E3 ligase ubiquitination 
sites on α-synuclein proteoforms (Figure 3d). In parallel, 
microfluidic diffusional sizing was used to determine directly 
in the solution state under native conditions the average hydro-
dynamic radius of the resulting ubiquitinated α-synuclein. 
The results demonstrate a time-dependent increase in the 
hydrodynamic radius of the ubiquitinated α-synuclein, com-
pared to pure ubiquitin or α-synuclein (Figure 3e), directly 
reporting on the increased ubiquitination over time. To the 
best of our knowledge, this is the first artificial cell mimicking 
the production of a purified post translationally modified pro-
tein of choice.
In conclusion, the artificial cell-on-a-chip presented here 
allows to perform central dogma activities in a confined and 
precisely regulated manner, thereby overcoming some of the 
major limitations of current synthetic biology approaches, such 
as controlled transcription and translation. We have success-
fully decoupled and confined transcription from translation, 
allowing regulation of transcription initiation and established 
an oscillating switch. In the future, the parallelization of mul-
tiple compartments can be applied for other central dogma 
activities, including translation and PTMs. In addition, we were 
able to translate α-synuclein, modify it with specific PTMs and 
characterize the resulting proteoforms, thereby identifying, for 
the first time, the ubiquitination sites of CHIP E3 ligase. The 
newly developed CONTRALL platform has thus been shown to 
allow tight regulation of the central dogma activities, which has 
previously been unattained using living systems. This platform 
can expand the current biological tool kit for the identification 
of PTMs sites. In addition, the possibility to add additional com-
partments to CONTRALL can potentially lead to the integra-
tion of other eukaryotic processes such as RNA splicing, thus 
further advance the field of artificial cells. We applied micro-
fluidics technology for the miniaturization and parallelization 
of experimental methodologies, granting significant advantages 
to control a wide range of in vitro processes and to study the 
effect of individual steps in protein expression and modifica-
tions.[23] Microfluidic approaches have been shown to be highly 
flexible in their design, allowing the adaptable coupling of a 
wide range of strategies into a single device. Thus, currently 
available approaches, such as on chip separation based on pro-
tein hydrodynamic radii[24] could be readily integrated within 
the CONTRALL platform to first allow the generation of a 
wide range of molecular species[25] and the subsequent on-chip 
characterization of their interactions in solution. Similarly, the 
aggregation process of proteins related to amyloid disorders 
can be studied in detail. Specifically, controlling PTMs and 
exploring the aggregation kinetics of different proteoforms by 
utilizing microdroplet-based approaches.[26] Furthermore, the 
CONTRALL platform facilitates the previously unattainable 
specific PTMs. By systematically introducing PTMs at specific 
sites, the products of the CONTRALL platform will allow us to 
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Figure 2. Decoupling of transcription and translation by mechanical promotor-like valves. a): i) Schematics of the two parallel transcription compart-
ments. ii) Schematics and bright field imaging of His-T7RP immobilized onto Ni beads trapped by pillars in the transcription compartments. Scale bar, 
50 µm. iii) Fluorescent image of mango light-up RNA aptamer in the detection channel. Scale bar, 100 µm. b) Fluorescence measurements of mango 
RNA aptamer and eGFP transcripts utilizing immobilized T7RP, using both biotinylated and nonbiotinylated PCR products as templates. c) Alternations 
in two controlled mechanical promotor-like valves resulting in an oscillating switch. d) Gradual accumulation of RNA transcripts demonstrating control 
over promotor strength of either a single (right) or two different (left) RNA aptamer transcripts.
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expand the currently available protein- and peptide-based mole-
cules, explore the hierarchical code of PTMs, their modulation 
of protein-protein interactions and the resulting aggregation 
propensity.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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Figure 3. Translation and characterization of purified His-eGFP and α-synuclein proteoforms. a): i) Schematics of the CONTRALL platform combining 
three hierarchical compartments. Confinement of processes in each compartment is secured by valves (red). Separate inlets allow the introduction 
of additional reagents. ii) Biotinylated DNA template encoding for His-tagged protein is injected into the transcription compartment containing 
immobilized T7RP. Following transcription, biotinylated DNA molecules and RNA transcripts are flown to the RNA transport compartment where 
biotinylated DNA molecules are immobilized on trapped SA beads, allowing RNA transcripts to continue to the translation compartment. Next, newly 
translated His-protein is immobilized onto Ni beads trapped in the translation and PTMs compartment, allowing the removal of translation compo-
nents and PTMs enzymes. iii) Fluorescent image of His-eGFP bound to Ni beads in the translation compartment. Scale bar, 100 µm. b) Fluorescence 
spectrum and Western blot (inset) of 1) purified His-eGFP, 2) collected flow-through, and 3) elution fraction. c) Western blot analysis of ubiquitinated 
α-synuclein produced by CONTRALL. Left: anti α-synuclein. Right: anti-ubiquitin. d) The newly identified CHIP E3 ligase ubiquitination sites denoted 
on the α-synuclein protein sequence (red arrows). e) Hydrodynamic radius measurements of ubiquitinated α-synuclein following different incubation 
times, compared to pure α-synuclein and pure ubiquitin.
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